Open AccessUsing subjective cognitive decline to identify high global amyloid in community‐based samples: A cross‐cohort study
Author(s) -
Buckley Rachel F.,
Sikkes Sietske,
Villemagne Victor L.,
Mormino Elizabeth C.,
Rabin Jennifer S.,
Burnham Samantha,
Papp Kathryn V.,
Doré Vincent,
Masters Colin L.,
Properzi Michael J.,
Schultz Aaron P.,
Johnson Keith A.,
Rentz Dorene M.,
Sperling Reisa A.,
Amariglio Rebecca E.
Publication year - 2019
Publication title -
alzheimer's and dementia: diagnosis, assessment and disease monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.497
H-Index - 37
ISSN - 2352-8729
DOI - 10.1016/j.dadm.2019.08.004
Subject(s) - apolipoprotein e , logistic regression , odds ratio , medicine , positron emission tomography , odds , cognitive decline , cohort , cognition , oncology , psychiatry , nuclear medicine , dementia , disease
We aimed to examine the contribution of subjective cognitive decline (SCD) to reduce the number of β‐amyloid (Aβ) positron emission tomography scans required for recruiting Aβ+ clinically normal individuals in clinical trials. Methods Three independent cohorts (890 clinically normal: 72 yrs ± 6.7; Female: 43.4%; SCD+: 24%; apolipoprotein E [ APOE ] ε4+: 28.5%; Aβ+: 32%) were used. SCD was dichotomized from one question. Using logistic regression, we classified Aβ+ using the SCD dichotomy, APOE ε4, sex, and age. Results SCD increased odds of Aβ+ by 1.58 relative to non‐SCD. Female APOE ε4 carriers with SCD exhibited higher odds of Aβ+ (OR = 3.34), whereas male carriers with SCD showed a weaker, opposing effect (OR = 0.37). SCD endorsement reduces the number of Aβ positron emission tomography scans to recruit Aβ+ individuals by 13% and by 9% if APOE ε4 status is known. Conclusion SCD helps to classify those with high Aβ, even beyond the substantial effect of APOE genotype. Collecting SCD is a feasible method for targeting recruitment for those likely on the AD trajectory.